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Medical	  applications	  of	  anticancer	  and	  antimalarial	  drugs	  often	  suffer	  from	  low	  aqueous	  solubility,	  high	  systemic	  toxicity,	  
and	   metabolic	   instability.	   Smart	   nanocarrier-­‐based	   drug	   delivery	   systems	   provide	   means	   of	   solving	   these	   problems	   at	  
once.	  Herein,	  we	  present	  such	  a	  smart	  nanoparticle	  platform	  based	  on	  self-­‐assembled,	  reduction-­‐responsive	  amphiphilic	  
graft	   copolymers,	   which	   were	   successfully	   synthesized	   through	   thiol-­‐disulfide	   exchange	   reaction	   between	   thiolated	  
hydrophilic	   block	   and	   pyridyl	   disulfide	   functionalized	   hydrophobic	   block.	   These	   amphiphilic	   graft	   copolymers	   self-­‐
assembled	   into	   nanoparticles	   with	   mean	   diameters	   of	   about	   30	   –	   50	   nm	   and	   readily	   incorporated	   hydrophobic	   guest	  
molecules.	  Fluorescence	  correlation	  spectroscopy	  (FCS)	  was	  used	  to	  study	  nanoparticle	  stability	  and	  triggered	  release	  of	  a	  
model	   compound	   in	   detail.	   Long-­‐term	   colloidal	   stability	   and	  model	   compound	   retention	   within	   the	   nanoparticles	   was	  
found	  when	  analyzed	  in	  cell	  media	  at	  body	  temperature.	  In	  contrast,	  rapid,	  complete	  reduction-­‐triggered	  disassembly	  and	  
model	  compound	  release	  was	  achieved	  within	  a	  physiological	  reducing	  environment.	  The	  synthesized	  copolymers	  revealed	  
no	  intrinsic	  cellular	  toxicity	  up	  to	  1	  mg/mL.	  Drug-­‐loaded	  reduction-­‐sensitive	  nanoparticles	  delivered	  a	  hydrophobic	  model	  
anticancer	  drug	   (doxorubicin,	  DOX)	   to	  cancer	  cells	   (HeLa	  cells)	  and	  an	  experimental,	  metabolically	  unstable	  antimalarial	  
drug	   (the	   serine	   hydroxymethyltransferase	   (SHMT)	   inhibitor	   (±)-­‐1)	   to	   Plasmodium	   falciparum-­‐infected	   red	   blood	   cells	  
(iRBCs),	  with	  higher	  efficacy	  compared	  to	  similar,	  non-­‐sensitive	  drug-­‐loaded	  nanoparticles.	  These	  responsive	  copolymer-­‐
based	   nanoparticles	   represent	   a	   promising	   candidate	   as	   smart	   nanocarrier	   platform	   for	   various	   drugs	   to	   be	   applied	   to	  
different	  diseases,	  due	   to	   the	  biocompatibility	  and	  biodegradability	  of	   the	  hydrophobic	  block,	  and	   the	  protein-­‐repellant	  
hydrophilic	  block.	  	  
Introduction	  
Nanoparticle-­‐assisted	   drug	   delivery	   allows	   for	   tuning	  
pharmacokinetics,	   toxicity,	   absorption,	   distribution,	  
metabolism,	  and	  excretion	  profile	  of	  drugs	  leading	  to	  different	  
needs	  for	  dosage	  and	  duration	  of	  treatment.1	  This	  concept	  has	  
been	   widely	   applied	   for	   improving	   clinical	   outcome	   of	  
anticancer	   therapy	   through	   increasing	   drug	   accumulation	   at	  
the	  target	  site	  while	  decreasing	  drug	  distribution	  to	  off-­‐target	  
sites.2,3	  Passive	  targeting	  of	  tumor	  tissue	  can	  be	  obtained	  using	  
non-­‐functionalized,	   drug-­‐loaded	   nanoparticles	   via	   the	  
enhanced	   permeability	   and	   retention	   (EPR)	   effect,	   which	  
allows	  nanoparticle	  accumulation	   in	   tumors	  after	   intravenous	  
application.4,5	   In	   terms	   of	   size,	   passive	   accumulation	   within	  
tumor	   tissue	   via	   the	   EPR	   effect	   is	   efficiently	   achieved	   with	  
long-­‐circulating	   nanoparticles	   ranging	   from	   10	   to	   100	   nm	   in	  
diameter.6	   However,	   small	   sized	   nanoparticles	   (sub-­‐50	   nm	  
diameter)	  have	  been	  shown	   to	  better	   target	  e.g.	   lymph	  node	  
metastatic	  cancer.7	  
Amphiphilic	   block	   copolymer	   (ABP)-­‐based	   nanomaterials	   are	  
one	   promising	   type	   of	   materials	   with	   broad	   applicability	   in	  
drug	   delivery.2,3	   Various	   self-­‐assembled	   nanostructures	  
ranging	   from	   micelles	   to	   worm-­‐like	   micelles	   to	   polymer	  
vesicles	  can	  be	  obtained	  in	  aqueous	  environments	  by	  carefully	  
choosing	   the	   type,	   architecture,	   lengths,	   and	  
hydrophilic/hydrophobic	   block	   ratio	   of	   ABPs.8-­‐10	   ABP-­‐based	  
nanoparticles	   benefit	   from	   lower	   critical	   micelle	  
concentrations	   (CMC),	   higher	   mechanical	   stability,	   simple	  
introduction	   of	   stimuli-­‐responsiveness	   within	   the	   ABP	  
architecture,	   and	   modification	   with	   targeting	   moieties	   when	  
compared	   to	   lipid	   based	   systems	   such	   as	   liposomes.3,11,12	  
Degradability	   of	   ABP-­‐based	   nanoparticles	   is	   introduced	   by	  
using	  polypeptides,	  polyphosphoesters,	  or	  polyesters,	   such	  as	  
poly(ε-­‐caprolactone)	   (PCL),	   as	   ABP	   hydrophobic	   building	  
blocks.13,14	  Poly(ethylene	  glycol)	  (PEG)	  is	  the	  most	  readily	  used	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polymer	   for	   the	   hydrophilic	   part	   of	   ABPs,	   due	   to	   the	  
biocompatibility	   and	   non-­‐fouling	   properties	   of	   this	   polymer,	  
needed	   for	   achieving	   long-­‐circulating	   nanoparticles.15	  
However,	  injection	  of	  PEG-­‐based	  nanostructures	  can	  induce	  an	  
immune	  response	  against	  PEG.16	  This	  significantly	  reduces	  the	  
efficacy	   of	   a	   PEG-­‐based	   drug	   delivery	   system,	   specifically	   for	  
repeated	   administration,16	   	   which	   highlights	   the	   urgent	   need	  
for	   alternative	   hydrophilic	   blocks	   to	   be	   exposed	   on	   drug	  
delivery	  vehicles.15,17,18	  
Another	   challenging	   aspect	   of	   nanoparticle-­‐based	   drug	  
delivery	   is	   the	   efficient	   release	   of	   the	   drug	   in	   the	   target	   cell,	  
while	   retaining	   the	   drug	   inside	   the	   nanostructure	   in	   the	  
extracellular	   environment.	   This	   is	   elegantly	   addressed	   by	  
spatiotemporal-­‐	   and	   dosage-­‐controlled	   delivery	   using	   stimuli-­‐
responsive	   materials	   and	   corresponding	   nanostructures.19-­‐21	  
Commonly	   used	   endogenous	   triggers	   for	   stimuli-­‐responsive	  
delivery	   are	   changes	   in	   pH,	   redox	   potential,	   and	   enzyme	  
concentration.19	   Reduction-­‐responsive	   ABP-­‐based	  
nanoparticles	   represent	   a	   unique	   class	   of	   smart	   materials	  
based	  on	  their	  effective	  delivery	  mechanism	  for	  a	  wide	  range	  
of	   molecules,	   such	   as	   nucleic	   acids22,23	   and	   low	   molecular	  
weight	   chemical	   drugs.24-­‐27	   The	   building	   blocks	   of	   these	  
nanostructures	  contain	  one	  or	  more	  disulfide	  linkage/s	  in	  their	  
main-­‐	   or	   side-­‐chains.	   This	   allows	   forming	   drug-­‐loaded	  
nanoparticles	   with	   stable	   morphology	   in	   circulation	   and	  
extracellular	   environments.	   After	   cellular	   uptake,	   rapid	  
cleavage	   of	   the	   disulfide	   linkage/s	   and	   subsequent	  
nanoparticle	  disassembly	  in	  the	  reductive	  cell	  cytosol	  promote	  
drug	   release.28	   The	   large	   gradient	   of	   the	   reducing	   agent	  
glutathione	   (GSH)	   across	   cell	   membranes	   –	   the	   cytosolic	  
concentration	  (2	  –	  10	  mM)	  is	  three	  orders	  of	  magnitude	  higher	  
than	   the	   extracellular	   concentration	   –	   serves	   as	   the	   basis	   for	  
reduction-­‐responsive	  anticancer	  drug	  delivery.29	  	  
Solubility,	   stability	   and	   toxicity	   problems	   are	   well	   known	   for	  
anticancer	   drugs,30	   but	   the	   same	   problems	   equally	   apply	   to	  
anti-­‐infectious	   agents,	   such	  as	   antimalarials.31,32	  Malaria	   is	   an	  
infectious	   disease	   caused	   by	   Plasmodium	   spp.	   parasites,	  
transmitted	   by	   Anopheles	   mosquitos.	   The	   disease	   causing	  
stages	   of	   the	   parasite	   infect	   and	   asexually	   divide	   inside	   of	  
human	   red	   blood	   cells	   (RBCs).33	   The	   need	   for	   novel	  
antimalarials	   or	   strategies	   against	   resistance	   development	   is	  
increasingly	   recognized.	   Especially	   since	   the	   recent	  
development	   and	   spread	   of	   resistance	   against	   the	   first-­‐line	  
treatment	   with	   artemisinin	   combination,34	   which	   already	   led	  
to	   treatment	   failures.35	  One	  proposed	  approach	   to	  overcome	  
the	   development	   of	   resistance	   is	   the	   delivery	   of	   high	   local	  
concentrations	   of	   antimalarials	   using	   e.g.	   nanoparticles.36,37	  
Current	   antimalarial	   drug	   delivery	   strategies	   are	   focused	   on	  
commercial	  antimalarials	  that	  have	  already	  been	  optimized	  for	  
in	  vivo	  applications.38,39	  	  
Surprisingly,	   there	   is	   evidence	   that	   proteins,	   such	   as	  
antibodies,40	   and	   small	   nanoparticles	   up	   to	   about	   80	   nm	  
diameter	   have	   direct	   access	   to	   the	   parasite	   inside	   the	  
RBC.36,41,42	   Several	   mechanisms	   for	   specific	   uptake	   of	   large	  
molecules	  and	  nanoparticles	  by	  parasitized	  RBCs	  compared	  to	  
RBCs	   have	   been	   proposed,43	   but	   this	   is	   an	   ongoing	  
controversy.	   Similarly	   to	   passive	   tumor	   targeting	   via	   the	   EPR	  
effect,	   this	   controversial	   “leakiness”	   of	   Plasmodium-­‐infected	  
RBCs	   (iRBCs)36,41,42	   can	   be	   exploited	   via	   a	   passive	   targeting	  
strategy	   using	   non-­‐functionalized,	   antimalarial-­‐loaded	  
nanoparticles.	   Also	   here,	   smaller	   sized	   nanoparticles	   (sub-­‐80	  
nm	  diameter)	  are	  needed,	  because	  the	  size-­‐cutoff	  to	  efficiently	  
reach	   intracellular	   malaria	   parasites	   of	   iRBCs	   is	   about	   80	  
nm.36,41,42	   The	   highly	   reducing	   parasite	   cytosol	   of	   iRBCs44	  
equally	  represents	  a	  valuable	  trigger	  for	  smart	  drug	  delivery	  of	  
antimalarials	  via	  reduction-­‐triggerable	  nanoparticles,	  similar	  to	  
reduction-­‐triggered	   anticancer	   drug	   delivery.	   Additionally,	  
drug-­‐resistant	   intracellular	  malaria	  parasites	  were	  reported	  to	  
possess	   even	   further	   increased	   cytosolic	   reduction	  
potentials.45,46	  
Herein,	   we	   introduce	   a	   novel,	   alternative	   type	   of	   ABP-­‐based	  
nanoparticles	   using	   a	   PEG-­‐alternative,	   poly(2-­‐methyl-­‐2-­‐
oxazoline)	   (PMOXA),	   as	   the	  hydrophilic	   block.	   Specifically,	  we	  
report	   the	   synthesis	   of	   a	   library	   of	   biodegradable,	   reduction-­‐
responsive	   ABPs	   composed	   of	   hydrophilic	   PMOXA	   and	  
hydrophobic	   PCL	  with	   grafted	  molecular	   architecture,	   poly(2-­‐
methyl-­‐2-­‐oxazoline)-­‐graft(SS)-­‐poly(ε-­‐caprolactone)	   (PMOXA-­‐
g(SS)-­‐PCL),	   in	   which	   the	   reduction-­‐responsive	   disulfide	   group	  
acts	   as	   the	   linker	   between	   PMOXA	   and	   PCL.	   Aqueous	   self-­‐
assembly	   of	   these	   graft	   copolymers	   into	   nanoparticles	   and	  
loading	   of	   cargo	   using	   model	   hydrophobic	   dye	   molecules	  
(Bodipy630,	  NileRed),	  anticancer	  drug	  (doxorubicin,	  DOX),	  and	  
antimalarial	   (serine	   hydroxymethyltransferase	   (SHMT)	  
inhibitor	   (±)-­‐1)32	   were	   studied	   (Scheme	   1).	   A	   single	  molecule	  
detection	   method,	   fluorescence	   correlation	   spectroscopy	  
(FCS),	  was	   used	   to	   demonstrate	   high	   stability	   and	  model	   dye	  
retention	   within	   self-­‐assembled	   nanoparticles	   in	   protein-­‐
containing	  cell	  media	  over	  four	  days	  and	  fast	  disassembly	  and	  
model	  compound	  release	  upon	  treatment	  with	  reducing	  agent.	  
Furthermore,	   the	   biocompatibility	   of	   these	   copolymers	   was	  
tested	   on	  HeLa	   cells	   in	   the	   range	   of	   0.1	  mg/mL	   to	   1	  mg/mL.	  
Anticancer	  drug-­‐loaded	  reduction-­‐sensitive	  nanoparticles	  were	  
evaluated	   for	   delivery	   of	   their	   payload	   to	   cancer	   cells	   (Hela)	  
and	  compared	  to	  non-­‐sensitive	  nanoparticles	  based	  on	  similar	  
polymers	  with	  linear	  architecture,	  PMOXA-­‐b-­‐PCL.	  Similarly,	  we	  
explored	   the	   nanoparticle-­‐based	   delivery	   of	   a	   non-­‐optimized,	  
hydrophobic,	   and	   metabolically	   unstable	   antimalarial	  
compound,	  which	   is	   in	  preclinical	  drug	  development	  stage,	   to	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iRBCs.	   The	   trigger	   for	   nanoparticle	   disassembly	   and	  
antimalarial	   release	   is	   the	   highly	   reducing	   cytosol	   of	  
intracellular	   parasites.	  We	   consider	   this	   nanoparticle-­‐assisted	  
delivery	  as	  a	  valuable	  additional	  avenue	  to	  medicinal	  chemistry	  
traditionally	   used	   to	   modify	   pharmacokinetic	   properties	   of	  
compounds	   via	   changing	   the	   chemical	   structure	   of	   the	  
compound	  itself.	  
Results	  and	  discussion	  
Graft	  copolymer	  synthesis	  and	  characterization	  
A	  novel	  graft	   copolymer	  was	  designed	  and	  synthesized	  based	  
on	  PMOXA	  hydrophilic	  polymer	  and	  PCL	  hydrophobic	  polymer	  
(Scheme	   2)	   to	   provide	   a	   reduction-­‐sensitive,	   biodegradable	  
building	  block	  for	  a	  nanoparticle	  platform	  to	  deliver	  anticancer	  
and	  antimalarial	  drugs	  via	  a	  triggered	  release	  mechanism.	  	  
PMOXA	   is	   considered	   a	   strong	   alternative	   to	   PEG,15,18,47-­‐49	  
which	  has	  mainly	  been	  used	  as	  hydrophilic	  block	   in	  ABPs,	  but	  
more	   recently,	   problems	   arose	  e.g.	   due	   to	   immune	   response	  
after	   repeated	   administration	   of	   PEG-­‐based	   systems.16	   This	  
highlights	  the	  urgent	  need	  for	  alternative	  copolymers	  for	  drug	  
delivery.	  The	  design	  of	  our	  graft	  copolymer	  has	  been	   inspired	  
by	   previous	   works	   that	   have	   demonstrated	   synthesis	   of	  
biodegradable,	   readily	   modifiable	   random	   copolymer	   of	  
poly(ε-­‐caprolactone)-­‐co-­‐poly(α-­‐carboxyl-­‐ε-­‐caprolactone)	   (PCL-­‐
co-­‐PCCL)50	   and	   pyridyl	   disulfide-­‐functionalized	   biodegradable	  
polymers	   to	   form	   reduction-­‐sensitive	   copolymers	   via	   thiol-­‐
disulfide	   exchange	   reaction.51	   In	   the	   present	   work,	   we	   first	  
synthesized	  thiolated	  PMOXA	  (PMOXA-­‐SH)	  through	  living	  ring-­‐
opening	   polymerization	   of	   2-­‐methyl-­‐2-­‐oxazoline	   and	   end	  
group	   functionalization,17	   which	   was	   then	   coupled	   via	   thiol-­‐
disulfide	   exchange	   reaction	   with	   pyridyl	   disulfide	  
functionalized	   poly(ε-­‐caprolactone)	   (PCL-­‐co-­‐PPCL)	   to	   obtain	  
the	   desired	   graft	   copolymer	   with	   reduction-­‐responsive	  
disulfide	  connection	  of	  hydrophobic	  and	  hydrophilic	  blocks.	  	  
Three	   PMOXA-­‐g(SS)-­‐PCL	   copolymers	   with	   different	  molecular	  
ratio	   (hydrophilic	   fraction,	   f(PMOXA))	   and	   molecular	   weights	  
were	  synthesized	  (Table	  1).	  A	  reduction-­‐insensitive	  copolymer	  
PMOXA-­‐b-­‐PCL	   was	   synthesized	   additionally	   to	   form	   non-­‐
triggered,	   biodegradable	   nanoparticles	   (Scheme	   S1,	   Fig.	   S5).	  
Detailed	   experimental	   procedures	   and	   polymer	  
characterization	   can	   be	   found	   in	   the	   Supplementary	  
Information.	  	  
The	  appearance	  of	  the	  peaks	  at	  2.34	  ppm	  and	  2.94	  ppm	  in	  the	  
1H	   NMR	   spectrum	   ((CD3)2SO)	   belonging	   to	   the	   protons	   on	  
methyl	  group	  of	  thiolacetate	  and	  methylene	  group	  next	  to	  the	  
thiol	   group	   indicated	   the	   successful	   reaction	   with	   potassium	  
thioacetate	  to	  obtain	  PMOXA-­‐SAc	  (Fig.	  S1A).52	  PMOXA-­‐SAc	  was	  
further	  activated	  by	  PPh3	  in	  anhydrous	  MeOH	  to	  yield	  PMOXA-­‐
SH,	  which	  was	  confirmed	  by	  the	  disappearance	  of	  the	  peaks	  at	  
2.34	  ppm	  (Fig.	  S1B).	  Fast	  manipulation	  was	  necessary	  to	  avoid	  
disulfide	  formation	  during	  the	  purification	  steps.	  	  
The	   hydrophobic,	   biodegradable	   PCL-­‐based	   copolymer	   part	  
with	   anchor	   points	   for	   hydrophilic	   polymers	   was	   synthesized	  
based	   on	   a	   modified	   protocol.50	   The	   appearance	   of	   1H	   NMR	  
signals	  at	  5.23	  ppm	  and	  7.26	  ppm	  belonging	  to	  the	  protons	  on	  
the	  methylene	  group	  next	  to	  benzyl	  group	  and	  protons	  on	  the	  
benzyl	   group	   demonstrated	   successful	   random	  
copolymerization	   of	   α-­‐benzyl	   carboxylate-­‐ε-­‐caprolactone	   and	  
ε-­‐caprolactone	   yielding	   poly(ε-­‐caprolactone)-­‐co-­‐poly(α-­‐benzyl	  
carboxylate-­‐ε-­‐caprolactone)	   (PCL-­‐co-­‐PBCL,	   Fig.	   S2B).	   The	  
corresponding	   molecular	   weights	   and	   dispersities	   (Đ),	   as	  
Scheme	  2	  The	  synthetic	  route	  for	  PMOXA-­‐SH,	  PCL-­‐co-­‐PPCL,	  and	  PMOXA-­‐g(SS)-­‐PCL.	  Reagents	  and	  conditions:	  (i)	  n-­‐butyllithium	  solution	  (2.5	  M	  in	  hexanes),	  benzyl	  chloroformate,	  
LiAlH4,	  THF,	  –75	  °C	  for	  3	  h	  under	  argon;	  (ii)	  methyl	  trifluoromethanesulfonate,	  2-­‐methyl-­‐2-­‐oxazoline,	  acetonitrile,	  80	  °C	  for	  24	  h	  under	  argon;	  (iii)	  potassium	  thioacetate,	  RT	  for	  24	  
h	   under	   argon	   (yield:	   92%);	   (iv)	   	   triphenylphosphine,	   anhydrous	   MeOH,	   RT	   for	   48	   h	   under	   argon	   (yield:	   85%);	   (v)	   anhydrous	   EtOH,	   ε-­‐caprolactone,	   α-­‐benzyl	   carboxylate-­‐ε-­‐
caprolactone,	   Zn(II)	   2-­‐ethylhexanoate,	   toluene,	  110	  °C	  for	  24	  h	  under	  argon	  (yield:	   82%);	   (vi)	   Pd/C	  (10	  wt.	  %),	   ethyl	   acetate,	  RT	  for	  42	  h	  under	  hydrogen	   (yield:	   85%);	  (vii)	   2-­‐
pyridylthiol	  cysteamine	  hydrochloride,	  N,N'-­‐dicyclohexylcarbodiimide	  (DCC),	  4-­‐dimethylaminopyridine,	  triethylamine,	  CH2Cl2,	  RT	  for	  60	  h	  under	  argon	  (yield:	  60%);	  (viii)	  PMOXA-­‐
SH,	  PCL-­‐co-­‐PPCL,	   acetic	   acid,	  DMF,	  RT	   for	  60	   h	  under	  argon	   (yield:	   38%).	   The	  yellow-­‐labeled	  disulfide	  bridge	   represents	   the	   reduction-­‐responsive	   chemical	   group	   connecting	  
hydrophobic	  (green)	  and	  hydrophilic	  block	  (blue).	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determined	   by	   1H	   NMR	   and	   gel	   permeation	   chromatography	  
(GPC)	   for	   two	   PCL-­‐co-­‐PBCLs,	   are	   listed	   in	   Table	   1.	  
Subsequently,	   PCL-­‐co-­‐PBCL	   was	   reduced	   by	   Pd/C	   under	  
hydrogen	  atmosphere	  to	  obtain	  PCL-­‐co-­‐PCCL	  as	  monitored	  by	  
the	   disappearance	   of	   the	   signals	   at	   5.23	   ppm	   and	   7.26	   ppm	  
belonging	  to	  the	  benzyl	  groups	  (Fig.	  S2B).50	  Finally,	  the	  PCL-­‐co-­‐
PCCL	  was	  reacted	  with	  2-­‐pyridylthio	  cysteamine	  hydrochloride	  
in	   presence	   of	   DCC	   as	   coupling	   agent	   to	   yield	   PCL-­‐co-­‐PPCL,	  
which	  was	  demonstrated	  by	   the	  appearance	  of	  peaks	  at	  2.93	  
ppm	  (methylene	  protons	  next	  to	  the	  disulfide	  group)	  and	  7.0–
8.6	  ppm	  (protons	  of	  the	  pyridyl	  group)	  (Fig.	  S2C).	  	  
PMOXA-­‐SH,	   PCL-­‐co-­‐PPCL,	   and	   a	   catalytic	   amount	   of	   acetic	  
acid51	   were	   subsequently	   used	   to	   synthesize	   the	   final	  
reduction-­‐sensitive	   amphiphilic	   graft	   copolymers	   PMOXA-­‐
g(SS)-­‐PCL	   through	   a	   thiol-­‐disulfide	   exchange	   reaction.	   After	  
precipitating	   the	  product	   in	   cold	  MeOH	   to	   remove	  unreacted	  
PMOXA-­‐SH,	   the	  coappearance	  of	   characteristic	  proton	   signals	  
of	   PMOXA	   and	   PCL	   indicated	   the	   successful	   synthesis	   of	   the	  
desired	   graft	   copolymer	   (Fig.	   S3).	   The	   signal	   at	   2.84	   ppm	  
corresponds	  to	  the	  protons	  on	  the	  carbon	  next	  to	  the	  disulfide,	  
which	   confirmed	   the	   reduction-­‐sensitive	   linkage	   within	   the	  
graft	   copolymer.	   FT-­‐IR	   was	   used	   to	   further	   characterize	   the	  
synthesized	   polymers	   and	   copolymers	   (Fig.	   S4).	   The	  
absorbance	   bands	   at	   1720	   cm-­‐1	   and	   1160	   cm-­‐1	   in	   the	   FT-­‐IR	  
spectrum	   of	   PMOXA-­‐g(SS)-­‐PCL	   were	   assigned	   to	   stretching	  
vibration	  of	  C=O	  and	  C-­‐O	  on	  PCL,	  and	  the	  band	  at	  1634	  cm-­‐1	  is	  
the	   characteristic	   vibration	   of	   C=O	   on	   PMOXA,	   additionally	  
indicating	   successful	   synthesis	   of	   PMOXA-­‐g(SS)-­‐PCL	  
copolymers.	   Interestingly,	   the	   molecular	   weight	   of	   PMOXA-­‐
g(SS)-­‐PCL	  1	  and	  PMOXA-­‐g(SS)-­‐PCL	  2	  determined	  from	  1H	  NMR	  
were	  higher	  compared	  to	  GPC	  data,	  which	  might	  be	  caused	  by	  
the	  grafted	  structure	  of	  the	  copolymer.51	  
	  
Self-­‐assembly	  and	  reduction-­‐triggered	  disintegration	  of	  PMOXA-­‐
g(SS)-­‐PCL	  nanoparticles	  
Nanoparticles	   were	   self-­‐assembled	   from	   reduction-­‐sensitive	  
PMOXA-­‐g(SS)-­‐PCLs	   graft	   copolymer	   to	   yield	   a	   triggerable	  
nanoparticle	   platform	   for	   the	   delivery	   of	   active	   compounds.	  
The	   solvent	   switch	   method	   was	   used	   for	   preparation	   of	  
nanoparticles	   by	   dropwise	   addition	   of	   phosphate	   buffered	  
saline	   (PBS)	   to	   stirred	   organic	   solutions	   (DMF)	   containing	  
dissolved	   graft	   copolymer.	   Subsequently,	   self-­‐assembly	   was	  
finalized	   and	   samples	   were	   purified	   by	   extensive	   dialysis	   in	  
aqueous	   solutions	   (physiological	   saline	   solution	   or	   PBS).	   The	  
obtained	   mean	   diameters	   of	   the	   self-­‐assembled,	   reduction-­‐
sensitive	  nanoparticles	  in	  PBS	  ranged	  from	  about	  27	  nm	  to	  51	  
nm	   with	   narrow	   PDI	   of	   0.09	   to	   0.18	   for	   all	   three	   graft	  
copolymers	   according	   to	   dynamic	   light	   scattering	   (DLS)	  
measurements	   in	   PBS	   (Fig.	   1C).	   Transmission	   electron	  
micrographs	  (TEM)	  confirmed	  the	  size	  and	  morphology	  of	  the	  
assembled	  spherical	  nanoparticles	  (Fig.	  1B,	  S6).	  These	  obtained	  
nanoparticle	   sizes	   lie	  within	   the	  optimum	   range	  of	   10	   to	   100	  
nm	   to	   be	   used	   as	   passively	   targeted	   drug	   delivery	   vehicles.6	  
The	  relatively	  small	  average	  size	  of	  maximum	  50	  nm	  provides	  
the	  basis	  for	  targeting	  cancer	  metastasis7	  and	  iRBCs	  in	  case	  of	  
malaria.36,41,42	  
Interestingly,	   the	   average	   diameter	   of	   self-­‐assembled	  
nanoparticles	   decreased	   with	   increasing	   hydrophilic	   content	  
(f(PMOXA),	   Fig.	   1C).	   This	   decrease	   can	   be	   attributed	   to	   the	   fact	  
that	   PMOXA-­‐g(SS)-­‐PCL	   copolymers	   with	   higher	   f(PMOXA)	   have	  
higher	   interfacial	   curvature	   values,	   which	   pushes	   the	   self-­‐
assembly	   towards	   smaller	   structures.8,9	   The	   CMC	   in	   PBS	   was	  
measured	  using	  pyrene	  as	  a	  fluorescent	  probe	  (Table	  1	  and	  Fig.	  
S7).53	   The	   CMC	   values	   increased	   with	   increasing	   fraction	   of	  
Table	  1	  Chemical	  characteristics	  of	  PCL-­‐co-­‐PBCLs	  and	  PMOXA-­‐g(SS)-­‐PCLs.	  
	   1H	  NMR	   GPC	   CMC	  
Polymer	   Block	  ratio	   Mn	   f(PMOXA)a	   Mw	   Mn	   Đ	   mg/mL	  
PCL-­‐co-­‐PBCL	  1	   264:13	   33360	   –	   40000	   19400	   2.0	   –	  
PCL-­‐co-­‐PBCL	  2	   126:3	   15150	   –	   13000	   19670	   1.50	   –	  
PMOXA-­‐g(SS)-­‐PCL	  2	   88:238	   34800	   22%	   22300	   13000	   1.72	   0.05*10-­‐3	  
PMOXA-­‐g(SS)-­‐PCL	  1	   127:165	   30000	   36%	   18400	   13260	   1.38	   0.20*10-­‐3	  
PMOXA-­‐g(SS)-­‐PCL	  3	   135:135	   27000	   43%	   –b	   –	   –	   0.29*10-­‐3	  
	  
a	  The	  values	  of	  f(PMOXA)	  were	  calculated	  by	  the	  equation   !"  !"  !"#$%!"  !"  !!!"#  !"#"$%&'(	  
b	  Due	  to	  solubility	  problems	  of	  PMOXA-­‐g(SS)-­‐PCL	  3	  in	  THF,	  no	  GPC	  data	  were	  obtained.	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hydrophilic	   domains,	   which	   is	   in	   agreement	   with	   previous	  
literature.9	  These	  CMC	  values	  are	   in	  general	  several	  orders	  of	  
magnitude	   lower	   compared	   to	  CMC	  values	   for	   low	  molecular	  
weight	   surfactants	   indicating	   much	   higher	   stability	   upon	  
dilution,	   which	   is	   desirable	   for	   long	   circulation	   and	   drug	  
retention	   within	   the	   nanocarrier	   after	   dilution	   in	   the	  
bloodstream.11	  
DLS	  was	  further	  used	  to	  investigate	  the	  reduction	  sensitivity	  of	  
PMOXA-­‐g(SS)-­‐PCL	   1	   self-­‐assembled	   nanoparticles	   by	   addition	  
of	  10	  mM	  reducing	  agent	  dithiothreitol	  (DTT)	  in	  PBS,	  which	  is	  a	  
standard	   method	   and	   concentration	   used	   in	   the	   field.54	   This	  
mimics	   the	   physiological	   cytosolic	   concentration	   of	   reducing	  
agent	   (10	  mM	   GSH)	   found	   in	   the	   reducing	   cytosol	   of	   cancer	  
cells.29	  Similarly,	  intracellular	  malaria	  parasites	  possess	  a	  highly	  
reducing	   cytosol.44	   DLS	   results	   demonstrated	   that	  
nanoparticles	   remained	   stable	   for	   at	   least	   24	   hours	   in	   the	  
absence	   of	   reducing	   agent,	   but	   were	   quickly	   destabilized	   by	  
reducing	  agent	  (Fig.	  2).	  	  
The	   diameter	   of	   reduction-­‐sensitive	   nanoparticles	   rapidly	  
increased	   after	   incubation	   in	   a	   physiological	   reducing	  
environment	  (Fig.	  2D),	  which	  was	  even	  apparent	  by	  eye	  due	  to	  
the	   increase	   in	   turbidity	   and	   subsequent	   formation	   of	   white	  
precipitation	   (Fig.	   2E).	   We	   speculated	   that	   these	   white	  
macroscopic	   precipitates	   (Fig.	   2E-­‐3)	   have	   resulted	   from	  
aggregation	   of	   insoluble	   PCL	   after	   cleavage	   of	   hydrophilic	  
blocks	  (PMOXA)	  from	  the	  copolymers.	  1H	  NMR	  confirmed	  this	  
theory,	   because	   we	   exclusively	   measured	   proton	   signals	  
characteristic	  for	  PCL,	  after	  filtering	  and	  washing	  the	  obtained	  
precipitate	   in	   MeOH	   	   (Fig.	   S8).	   These	   results	   clearly	   indicate	  
that	   the	   disulfide	   bridge	   between	   PMOXA	   and	   PCL	   was	  
reduced	  in	  the	  presence	  of	  DTT,	  which	  led	  to	  disintegration	  of	  
nanoparticles.	   Additionally,	   TEM	   images	   confirmed	  
nanoparticle	  stability	  at	  37	  °C	  for	  at	  least	  31	  h	  (Fig.	  2B).	  In	  the	  
presence	  of	  reducing	  agent	  nanoparticles	  disassembled	  –	  they	  
were	   not	   visible	   in	   TEM	   images	   anymore	   –	   and	   only	   few	  
polymer	   aggregates	   remained	   (Fig.	   2C,	  white	   arrow	  points	   to	  
one	   aggregate).	   This	   nanoparticle	   design	   allows	   reduction-­‐
triggered	   disassembly,	   subsequent	   degradation	   of	   remaining	  
hydrophobic	  polyester	  blocks	  (PCL)	  over	  time,	  and	  excretion	  of	  
hydrophilic	   PMOXA	   chains	   via	   kidneys,	   as	   e.g.	   demonstrated	  
for	   similar	   PEG	   chains	   up	   to	   30	   kDa,55	   demonstrating	   the	  
suitability	   of	   these	   copolymers	   for	   biomedical	   applications.	  
Furthermore,	   our	   nanoparticle	   platform	   provides	   an	  
alternative	   to	   PEG-­‐based	   nanoparticles,	   which	   are	   currently	  
being	  proposed	  for	  many	  drug	  delivery	  applications,	  but	  these	  
need	   to	   be	   replaced	   by	   other	   types	   due	   to	   adverse	   effects	  
after	  repeated	  administration	  of	  structures	  based	  on	  PEG.16	  
	  
Loading	  of	  various	  hydrophobic	  model	  molecules	  within	  
nanoparticles	  	  
Various	   hydrophobic	   cargo	   molecules	   were	   chosen	   to	   be	  
incorporated	   within	   the	   hydrophobic	   core	   of	   self-­‐assembled	  
nanostructures	   for	   stabilization	   and	  protection	  purposes.	   The	  
fluorescent	   dye	   molecules	   Bodipy630	   and	   NileRed,	   the	  
anticancer	   drug	   doxorubicin	   (DOX),	   and	   the	   experimental,	  
metabolically	   unstable	   antimalarial	   (SHMT	   inhibitor	   (±)-­‐1)32	  
were	   the	   selected	   compounds	   for	   encapsulation	   in	  
nanoparticles	   formed	   by	   reduction-­‐sensitive	   PMOXA-­‐g(SS)-­‐
PCLs	   and	   PMOXA-­‐b-­‐PCL.	   Non-­‐triggered	   PMOXA-­‐b-­‐PCL-­‐based	  
nanoparticles	   served	   as	   biodegradable,	   but	   reduction	  
insensitive	   control	   nanostructures.	   All	   these	   hydrophobic	  
molecules	   were	   readily	   incorporated	   into	   the	   hydrophobic	  
core	  of	  all	  the	  different	  nanoparticles.	  Drug	  loading	  efficiencies	  
(DLE)	  of	  15%,	  30%,	  40%,	  and	  55%	  for	  NileRed,	  Bodipy630,	  DOX,	  
and	   SHMT	   inhibitor	   (±)-­‐1,	   respectively,	   were	   measured	   by	  
fluorescence	   (DOX,	   Fig.	   S9)	   and	  UV-­‐Vis	   absorbance	   (dyes	   and	  
antimalarial,	   Fig.	   S11)	   measurements	   for	   reduction-­‐sensitive	  
nanoparticles.	   DLS	   measurements	   of	   drug/dye-­‐loaded	  
nanoparticles	   revealed	   typical	   average	   diameters	   of	   42	   ±	   11	  
nm	   for	   reduction-­‐sensitive	   nanoparticles	   and	   74	   ±	   24	   nm	   for	  
similar,	  non-­‐sensitive	  nanoparticles	  (Fig.	  S10,	  S13).	  TEM	  images	  
confirmed	  these	  sizes	  (Fig.	  S12,	  S13).	  
Encapsulation	   of	   one	  model	   compound	   (DOX)	  was	   studied	   in	  
more	   detail	   (Table	   S1).	   Nanoparticles	   from	   all	   three	   PMOXA-­‐
g(SS)-­‐PCL	  1	  –3	  were	  loaded	  with	  various	  DOX	  feeding	  amounts	  
and	  with	   theoretical	   drug	   loading	   contents	   (DLC)	   of	   4.8	  wt%,	  
13	   wt%	   and	   20	   wt%.	   Interestingly,	   the	   DLEs	   were	   always	  
around	   40%	   for	   all	   the	   samples,	   which	   indicated	   that	   the	  
theoretical	   DLCs	   and	   the	   difference	   of	   polymer	   chemical	  
structure	  had	  very	   little	   influence	  on	  DLE	  (Table	  S1).	  The	  40%	  
DLE	  was	   slightly	   lower	   than	   the	   values	   (DLE	   >	   50%)	   reported	  
for	  nanoparticles	  based	  on	  cross-­‐linked	  polyurethane	  micelles	  
(CCL-­‐PUMs)	   and	   PCL-­‐g-­‐SS-­‐PEG	   copolymers	   (1H	   NMR:	   35600	  
g/mol–66000	   g/mol),24,51	   which	   is	   explained	   by	   the	   non-­‐
crosslinkable	  structure	  and	   lower	  molecular	  weight	  molecular	  
structure	  of	  our	  PMOXA-­‐g(SS)-­‐PCLs.	  However,	  our	  copolymers	  
Fig.	   2	   Reduction	   triggered	   disassembly	   of	   PMOXA-­‐g(SS)-­‐PCL	   nanoparticles.	   (A)	  
Schematic	  disassembly	  process	  showing	  the	  cleavage	  of	  the	  disulfide	  bonds	  leading	  
to	   free	   PMOXA-­‐SH	   (blue)	   and	   PCL	   (green).	   (B)	   TEM	   of	   PMOXA-­‐g(SS)-­‐PCL	   1	  
nanoparticles	  after	   incubation	  in	  PBS	  at	  37	  °C	  for	  31	  h.	  (C)	  TEM	  image	  of	  the	  same	  
sample	  after	   incubation	  in	  PBS	  containing	  10	  mM	  DTT	  at	  37	  °C	  for	  31	  h.	  The	  white	  
arrow	   indicates	   a	   PCL	   aggregate	   (1H	   NMR,	   Fig.	   S8).	   (D)	   Changes	   in	   diameter	   of	  
nanoparticles	  self-­‐assembled	   from	  PMOXA-­‐g(SS)-­‐PCL	  1	   in	   time	  response	   to	  10	  mM	  
DTT	  as	  measured	  by	  DLS;	  only	  in	  the	  presence	  of	  DTT	  the	  diameter	  rapidly	  shifted	  to	  
very	  large	  values	  (red,	  blue	  curve),	  at	  time	  point	  0	  (black	  curve)	  and	  after	  incubation	  
without	  DTT	  for	  24	  h	  (green	  curve)	  the	  nanoparticles	  appeared	  similarly.	  (E)	  Digital	  
images	   of	   nanoparticle	   solution	   formed	   by	   PMOXA-­‐g(SS)-­‐PCL	   1	   (1	  mg/mL)	   in	   DLS	  
cuvettes	   in	   a	   time	   series	   after	   10	   mM	   DTT	   treatment.	   (1)	   13	   minutes,	   	   (2)	   47	  
minutes,	  and	  (3)	  4	  h.	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are	   synthesized	   via	   a	   simpler	   synthesis	   route,	   which	   would	  
overcompensate	   for	   a	   slightly	   lower	   DLE.	   Our	   results	   further	  
demonstrated	   that	   the	   nanoparticles	  were	   loaded	  with	  more	  
drugs	  (DLC	  increases)	  when	  more	  drugs	  were	  fed	  (Table	  S1).	  In	  
this	   respect,	   the	   final	   diameters	   and	   polydispersity	   indices	  
(PDI)	   of	   DOX-­‐loaded	   nanoparticles	   slightly	   increased	   with	  
increasing	   drug	   feed	   for	   all	   three	   PMOXA-­‐g(SS)-­‐PCL	  
copolymers	  (Table	  S1	  and	  Fig.	  S10),	  which	  was	  caused	  by	  more	  
encapsulated	   DOX	   occupying	   more	   spatial	   area	   in	   the	  
nanoparticle	   core,	   which	   is	   in	   agreement	   with	   previously	  
reported	  results.51	  
	  
Reduction-­‐triggered	  model	  compound	  release	  and	  stability	  of	  
nanoparticles	  in	  cell	  media	  	  
The	  design	  of	  smart	  drug	  delivery	  vehicles	  demands	  for	  stable	  
nanostructures,	  which	  do	  not	  aggregate,	  keep	  the	  drug	  within	  
the	   carrier	   prior	   to	   cellular	   uptake,	   and	   subsequently	   release	  
the	  payload	  upon	  reaching	  cellular	  compartments	  that	  provide	  
the	  desired	   trigger.	   FCS	   is	   a	  method	   that	   allows	   to	   study	  dye	  
encapsulation,	   stability	   and	   triggered	   release	   on	   a	   single	  
molecule	   level.56,57	   FCS	   was	   used	   herein	   to	   first	   follow	   the	  
reduction-­‐triggered	   disintegration	   of	   reduction-­‐responsive	  
nanoparticles	   formed	   from	   PMOXA-­‐g(SS)-­‐PCLs	   and	   release	  
behavior	   of	   a	   model	   hydrophobic	   cargo	   (Bodipy630)	   upon	  
treatment	  with	   reducing	  agents	   (DTT	  or	  GSH)	  at	  physiological	  
concentrations.	   It	   can	   be	   determined	   whether	   the	   dye	   is	  
encapsulated	   or	   freely	   diffusing	   by	   following	   the	   diffusion	  
times	   (τD)	  of	   fluorescent	  molecules.	  Time	  series	  of	  FCS	  curves	  
were	  recorded	  in	  the	  presence	  or	  absence	  of	  reducing	  agent	  to	  
follow	   reduction-­‐triggered	   model	   compound	   release	   from	  
triggered	   nanoparticles	   compared	   to	   a	   non-­‐triggered	  
nanoparticle	   version	   (Fig.	   3,	   S14).	   The	   fraction	   of	   free	   dye	  
versus	  encapsulated	  dye	  was	  followed	  using	  a	  two-­‐component	  
fit	   of	   the	   obtained	   autocorrelation	   curves	   (Fig.	   3A).	  
Simultaneously,	   the	   hydrodynamic	   diameters	   of	   the	  
nanoparticles	   and	   the	   number	   of	   dye	   molecules	   per	   single	  
nanoparticle	  were	  calculated	  from	  the	  diffusion	  times	  (τD)	  and	  
molecular	   brightness	   (counts	   per	   molecule,	   CPM	   in	   kHz),	  
respectively,	   by	   comparing	   values	   of	   nanoparticles	   to	   values	  
obtained	   for	   free	   dye.	   The	   obtained	   nanoparticle	  
hydrodynamic	  diameters	  using	  FCS	   (Fig.	  3B,	   S14C,	   S15)	  are	   in	  
good	  agreement	  with	  values	  measured	  by	  DLS	  and	  TEM	  (Fig.	  1,	  
S10,	   S12,	   S13).	   Furthermore,	   the	   reducing	   agent-­‐induced	  
increase	   of	   nanoparticle	   sizes	   for	   the	   reduction-­‐sensitive	  
copolymers	  was	  confirmed	  by	  FCS	  (Fig.	  S14).	  
The	  reduction-­‐triggered	  release	  of	  a	  model	  cargo	  (Bodipy630)	  
from	  all	  reduction-­‐sensitive	  nanoparticles	  compared	  to	  stable,	  
non-­‐sensitive	   nanoparticles	   was	   successfully	   achieved	   as	  
demonstrated	  by	  FCS	  measurements	  (Fig.	  3A,B,	  S14A,B,D).	  The	  
free	   dye	   population	   obtained	   from	   two	   component	   fits	   was	  
only	   increasing	  over	   time	  –	   reaching	  more	  than	  90%	  free	  dye	  
after	  1.5	  h	  –	   in	  case	  of	  PMOXA-­‐g(SS)-­‐PCL	  nanoparticles	   in	  the	  
presence	  of	  DTT	  (10	  mM).	  The	  release	  from	  PMOXA-­‐g(SS)-­‐PCL	  
nanoparticles	   was	   slower	   when	   the	   physiological	   reducing	  
agent	   GSH	   (10	  mM)	   was	   used	   (7	   h	   to	   reach	   about	   90%	   free	  
dye,	   Fig.	   S14D).	   	   This	   is	   explained	   by	   the	   weaker	   reducing	  
potential	   of	   GSH	   compared	   to	   DTT58	   and	   the	   formation	   of	  
glutathione	  disulfides	   (GSSG)	   in	  buffer.	  However,	   intracellular	  
conditions	   are	   much	   more	   complex,	   including	   other	   redox	  
molecules,	   many	   proteins/enzymes	   including	   glutathione	  
reductase,	  which	  maintains	   the	   reducing	   potential	  within	   the	  
cell	  cytosol.59	  	  
The	   same	   PMOXA-­‐g(SS)-­‐PCL	   nanoparticles	   samples	   incubated	  
without	   reducing	   agent	   or	   non-­‐sensitive	   nanoparticles	  
(PMOXA-­‐b-­‐PCL)	  with	   reducing	  agent	   (10	  mM	  DTT	  or	  GSH)	  did	  
not	  reveal	  a	  free	  dye	  population	  in	  FCS	  curves	  even	  after	  24	  h.	  
This	   smart	   compound	   release	   from	   nanoparticles	   at	  
physiological,	   cytosolic	   reducing	  agent	   concentration	  at	  37	   °C	  
sets	   the	   basis	   for	   triggered	   delivery	   of	   hydrophobic	   and	  
unstable	   drug	  molecules	   to	   cancer	   cells	   and	  malaria	   parasite	  
infected	  RBCs.	  
Before	   cell	   experiments	   were	   conducted,	   the	   stability	   of	   the	  
loaded	  nanocarriers	  was	  studied	  in	  detail	  on	  a	  single	  molecule	  
level	   using	   FCS.	   These	   measurements	   were	   performed	   at	  
physiological	   temperature	   (37	  °C)	  under	  shaking	  conditions	   in	  
the	   complete	   cell	   media	   (containing	   proteins),	   which	   were	  
subsequently	   used	   for	   assays	   with	   cancer	   cells	   and	   malaria	  
Fig.	   3	   Reduction-­‐triggered	   disassembly	   and	   dye	   release	   from	   PMOXA-­‐g(SS)-­‐PCL	  
nanoparticles	   and	   nanoparticle	   cell	   medium	   stability	   studied	   by	   fluorescence	  
correlation	   spectroscopy	   (FCS).	   (A)	   Normalized	   autocorrelation	   curves	   (symbols)	  
and	  fits	  (lines)	  from	  FCS	  measurements	  using	  Bodipy630-­‐loaded	  PMOXA-­‐g(SS)-­‐PCL	  
1	   nanoparticles	   in	   absence	  and	   presence	   of	   10	  mM	  DTT	   in	   PBS:	   t	   =	  0	  min	   (blue	  
circles,	  0%	  free	  dye	  fraction),	  t	  =	  24	  min	  (red	  crosses,	  46%	  free	  dye	  fraction),	  t	  =	  24	  
h	   (black	   diamonds,	   100%	   free	   dye	   fraction),	   t	   =	   24	   h	   without	   DTT	   (magenta	  
triangles,	   0%	   free	   dye	   fraction).	   (B)	   Time	   series	   of	   the	   percentage	   of	   free	   dye	  
fraction	  from	  FCS	  curves	  of	  nanoparticles	  in	  PBS	  with/without	  10	  mM	  DTT	  at	  37	  °C.	  
Free	   dye	  was	   only	   appearing	   for	   PMOXA-­‐g(SS)-­‐PCL	   in	   presence	   of	   DTT,	   whereas	  
incubation	  in	  PBS	  or	  non-­‐sensitive	  PMOXA-­‐b-­‐PCL-­‐nanoparticles	   in	  10	  mM	  DTT	  did	  
not	   show	   free	  dye	  up	   to	  24	  h	   incubation.	  Values	  are	  mean	  of	  three	  independent	  
measurements	   ±	   SEM	   for	   each	   time	   point.	   (C)	   Stability	   of	   PMOXA-­‐g(SS)-­‐PCL	   3	  
Bodipy630-­‐loaded	  nanoparticles	   in	  malaria	  culture	  medium	  (MCM)	  at	  37	  °C	  under	  
shaking	   conditions	   for	   four	   days;	   nanoparticle	   fraction	   from	   two-­‐component	  
autocorrelation	  curve	  fitting	  compared	  to	  time	  point	  0	  (grey	  diamonds),	  change	  in	  
number	  of	  dye	  molecules	  per	  nanoparticles	  calculated	   from	  molecular	  brightness	  
(CPM)	   data	   compared	   to	   time	   point	   0	   (black	   squares),	   and	   hydrodynamic	  
nanoparticle	   diameter	   (Dh)	   calculated	   from	   obtained	   diffusion	   times	   (blue	  
triangles).	   Data	   for	   the	   other	   copolymers,	   time	   series	   of	   nanoparticle	   Dh	   in	  
presence	  or	  absence	  of	  DTT,	  and	  stability	  in	  both	  cancer	  cell	  medium	  and	  MCM	  can	  
all	  be	  found	   in	  SI	  (Fig.	  S14,	  S15).	  Values	  are	  mean	  of	  30	  curves	  ±	   SD	  at	  each	  time	  
point.	  Statistics	  was	  analyzed	  using	  two-­‐tailed	  Student’s	  t-­‐test.	  

















Nanoscale	   	  ARTICLE	  
This	  journal	  is	  ©	  The	  Royal	  Society	  of	  Chemistry	  20xx	   J.	  Name.,	  2013,	  00,	  1-­‐3	  |	  7 	  
Please	  do	  not	  adjust	  margins	  
Please	  do	  not	  adjust	  margins	  
parasites.	  Reduction-­‐sensitive	  and	  non-­‐sensitive	  nanoparticles	  
were	  both	  highly	  stable	  in	  terms	  of	  nanoparticle	  size,	  colloidal	  
stability,	   and	   dye	   retention	   within	   the	   nanoparticles	   in	   both	  
cell	   media	   for	   the	   whole	   tested	   time	   window	   of	   four	   days,	  
which	  was	   the	  maximum	   incubation	   time	   used	   in	   cell	   assays	  
(Fig.	   3C,	   S15).	   Overall,	   all	   the	   nanoparticle	   samples	   did	   not	  
reveal	   any	   dye	   release	   throughout	   the	   whole	   assay	   time	   as	  
calculated	  from	  two	  component	  fits	  of	  autocorrelation	  curves,	  
which	   did	   not	   yield	   any	   significant	   fractions	   of	   fast	   diffusing	  
species	  (grey	  diamonds,	  Fig.	  3C,	  S15).	  The	  diffusion	  time	  of	  this	  
fast	  diffusing	   component	  was	   fixed	   to	   typical	   values	  of	   about	  
300	   µs,	   which	   is	   different	   to	   free	   dye	   diffusion	   due	   to	  
interaction	  of	  media	  proteins	  with	  hydrophobic	  dye	  molecules	  
as	  calibrated	  by	  FCS	  of	  dye	  in	  complete	  cell	  media.	  An	  average	  
of	   18%	   and	   2%	  dye	   release	  was	   calculated	   at	   the	   end	   of	   the	  
four-­‐day	  assay	  in	  case	  of	  reduction-­‐sensitive	  and	  non-­‐sensitive	  
nanoparticles,	  respectively,	  when	  comparing	  the	  change	  in	  the	  
number	   of	   dye	   molecules	   per	   nanoparticle,	   via	   CPM	  
comparison	  of	   free	  dye	   to	  nanoparticle	   values	  over	   time.	  But	  
these	   small	   differences	   compared	   to	   time	   point	   zero	   were	  
mostly	   not	   significant	   (Fig.	   S15).	   The	   nanoparticle	  
hydrodynamic	  diameters	  (Dh)	  remained	  similar	  for	  all	  samples	  
over	   the	   whole	   time	   course	   of	   four	   days,	   remaining	   in	   the	  
optimal	  size	  window	  of	  Dh	  =	  10	  to	  100	  nm	  needed	  for	  optimal	  
drug	  delivery	  via	  passive	  targeting.6	  This	  was	  expected	  due	  to	  
the	   protein-­‐repellant	   PMOXA15,18	   hydrophilic	   blocks	   exposed	  
on	  the	  nanoparticle	  surfaces.	  This	  is	  an	  important	  aspect,	  since	  
nanoparticle	   aggregation	   would	   significantly	   hamper	  
accessibility	   of	   nanoparticles	   to	   tumor	   sites	   and	   iRBCs.	   Blood	  
circulation	   times	   in	   vivo	   –	   needed	   for	   efficient	   passive	  
accumulation	  of	   the	  drug-­‐loaded	  nanoparticles	  at	   tumor	  sites	  
or	   within	   iRBCs	   –	   would	   also	   be	   reduced	   due	   to	   increased	  
hepatosplenic	   filtration.	   This	   demonstrates	   the	  high	  potential	  
of	  triggered	  nanoparticles	  based	  on	  PMOXA	  hydrophilic	  blocks	  
that	   can	   be	   seen	   as	   valuable	   alternatives	   to	   overcome	  
problems	  associated	  with	  PEG-­‐based	  nanoparticles.16	  	  
Fig.	   4	   Polymer	   biocompatibility,	   uptake	   and	   release	   of	   DOX	   from	   DOX-­‐loaded	   reduction-­‐sensitive	   PMOXA-­‐g(SS)-­‐PCL	   nanoparticles.	   (A)	   Schematic	   process	   of	   nanoparticle	  
uptake	  and	   reduction-­‐triggered	  (GSH)	  disassembly	  of	  nanoparticles	  and	  drug	  release.	  (B,	  C)	  CLSM	   images	  of	   intracellular	  DOX	  release	   from	   the	   reduction-­‐responsive,	  DOX-­‐
loaded	  PMOXA-­‐g(SS)-­‐PCL	  2	  nanoparticles	  using	  HeLa	  cells	  after	  1	  h	  of	  incubation.	  For	  each	  panel,	  images	  from	  left	  to	  right	  show	  cell	  nuclei	  stained	  by	  Hoechst	  33342	  (blue),	  
DOX	  fluorescence	  in	  cells	  (red)	  and	  overlays	  of	  the	  two	  images.	  (B)	  DOX	  loaded	  PMOXA-­‐g(SS)-­‐PCL	  2	  nanoparticles	  (0.25	  µg/mL	  DOX),	  (C)	  free	  DOX	  as	  control	  (0.25	  µg/mL	  DOX).	  
Scale	  bars	  are	  50	  µm.	  (D)	  Viabilities	  of	  HeLa	  cells	  after	  incubation	  with	  empty	  PMOXA-­‐g(SS)-­‐PCL	  nanoparticles	  for	  48	  h	  demonstrating	  absence	  of	  apparent	  polymer	  toxicity.	  All	  
the	  data	  are	  presented	  as	  average	  ±	  SD	  (n	  =	  4).	  (E)	  Viability	  of	  HeLa	  cells	  incubated	  with	  DOX-­‐loaded	  PMOXA-­‐g(SS)-­‐PCL	  nanoparticles,	  DOX-­‐loaded	  PMOXA-­‐b-­‐PCL	  nanoparticles,	  
and	  free	  DOX	  for	  48	  h.	  The	  average	  for	  all	  three	  PMOXA-­‐g(SS)-­‐PCL	  1	  –	  3	  is	  given,	  due	  to	  non-­‐significant	  differences	  between	  the	  samples.	  All	  the	  data	  are	  presented	  as	  the	  
average	  ±	  SEM	  (n	  ≥	  3).	  	  Statistics	  were	  analyzed	  using	  two-­‐tailed	  Student’s	  t-­‐test:	  *P<0.05,	  **P<0.01,	  ***P<0.001.	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Graft	  copolymer	  biocompatibility	  and	  drug	  delivery	  studies	  
with	  cancer	  cells	  	  
Primary	   evaluation	   of	   our	   reduction-­‐sensitive	   nanoparticle	  
platform	  for	  the	  smart	  delivery	  of	  drugs	  was	  performed	  on	  an	  
in	  vitro	  cancer	  cell	  model	   (Fig.	  4).	  First,	  cellular	   toxicity	  of	   the	  
synthesized	   graft	   copolymers	   was	   tested	   on	   HeLa	   cells	   using	  
cell-­‐viability	  assays.	  These	  assays	  demonstrated	  that	  the	  three	  
PMOXA-­‐g(SS)-­‐PCL	   copolymers	  were	   not	   toxic	   to	  HeLa	   cells	   in	  
the	  concentration	  range	  of	  0.1	  mg/mL	  up	  to	  1	  mg/mL	  after	  48	  
h	   incubation	   (Fig.	   4D).	   This	   confirms	   biocompatibility	   of	   this	  
new	  copolymer	  at	  the	  cellular	  level	  confirming	  its	  potential	  as	  
a	   valuable	   candidate	   for	   smart	   drug	   delivery	   research	   and	  
applications.	   Next,	   drug-­‐loaded	   (DOX)	   nanoparticles	   were	  
tested	   on	   HeLa	   cells	   to	   validate	   triggered	   drug	   delivery	   to	  
cancer	  cells	  (Fig.	  4,	  S16,	  S17,	  S18).	  
Confocal	   laser	   scanning	   microscopy	   (CLSM)	   was	   used	   to	  
investigate	  cellular	  uptake	  and	  intracellular	  release	  behavior	  of	  
DOX-­‐loaded	  PMOXA-­‐g(SS)-­‐PCL	  nanoparticles	  in	  HeLa	  cells	  over	  
the	   time	   course	   of	   8	   h	   (Fig.	   4B,	   S16A,	   S17A,	   S18A).	   DOX	  
intercalates	  with	  cellular	  DNA	  when	  released	  in	  cells	  causing	  a	  
co-­‐localization	   of	   fluorescence	   signals	   of	   DOX	   and	   the	   DNA-­‐
stain.60	  CLSM	  images	  demonstrate	  that	  DOX	  has	  been	  released	  
from	   DOX-­‐loaded	   PMOXA-­‐g(SS)-­‐PCL	   2	   nanoparticles	   (0.25	  
µg/mL	   DOX)	   and	   it	   has	   been	   transferred	   to	   the	   cell	   nucleus	  
within	   only	   one	   hour	   (Fig.	   4B).	   This	   indicates	   fast	  
internalization	  of	  DOX-­‐loaded	  nanoparticles	  and	   rapid	   release	  
of	   DOX	   inside	   cells.	   These	   findings	   are	   comparable	   with	   free	  
DOX	  (0.25	  µg/mL	  DOX),	  which	  also	  mainly	  accumulated	  in	  the	  
cell	  nucleus	  after	  1	  h	  (Fig.	  4C).	  The	  fast	  release	  was	  attributed	  
to	   the	   disulfide	   bond	   cleavage	   in	   the	   presence	   of	   high	  
concentration	   of	   GSH	   (2–10	   mM)	   in	   the	   intracellular	  
compartment	   of	   cancer	   cells,29	   as	   demonstrated	   in	   the	  
previous	   sections	   by	   extracellular	   NMR,	   DLS,	   TEM,	   and	   FCS	  
measurements	  in	  10	  mM	  DTT	  and	  10	  mM	  GSH	  in	  case	  of	  FCS.	  
The	   faster	   intracellular	   release	   of	   DOX	   compared	   to	   the	  
extracellular	   FCS	  measurements	  with	   10	  mM	  GSH	   (Fig.	   S14D)	  
are	   explained	   by	   the	   much	   more	   complex	   intracellular	  
environment	  as	  explained	  above.59	  	  	  
DOX-­‐loaded,	   reduction-­‐sensitive	   PMOXA-­‐g(SS)-­‐PCL	  
nanoparticles	   exhibited	   a	   higher	   anti-­‐proliferation	   effect	   on	  
HeLa	  cells	  compared	  to	  the	  non-­‐sensitive	  DOX-­‐loaded	  PMOXA-­‐
b-­‐PCL	   nanoparticles	   at	   concentrations	   that	   led	   to	   significant	  
reduction	   of	   cell	   viability	   in	   case	   of	   nanoparticles	   after	   48	   h	  
incubation	  (4.5	  and	  9	  µg/mL	  DOX,	  Fig.	  4E).	  This	  was	  attributed	  
to	  the	  fast,	  triggered,	  and	  efficient	  release	  form	  PMOXA-­‐g(SS)-­‐
PCL	  nanoparticles	  compared	  to	  a	  slower,	   less	  efficient	  release	  
from	  non-­‐triggered,	  biodegradable	  nanoparticles	  formed	  from	  
PMOXA-­‐b-­‐PCL.	  This	  explains	  the	  benefit	  of	  the	  reducible	  group	  
in	  PMOXA-­‐g(SS)-­‐PCL	  compared	  to	  the	  non-­‐sensitive	   linkage	   in	  
PMOXA-­‐b-­‐PCL.	   PMOXA-­‐b-­‐PCL	   serves	   as	   a	   control	   to	   estimate	  
the	   release	   from	  nanoparticles	   built	   from	  PMOXA	  and	  PCL	   in	  
the	   absence	   of	   a	   responsive	   group.	   There	   was	   no	   difference	  
observed	   between	   the	   three	   different	   PMOXA-­‐g(SS)-­‐PCL	  
nanoparticles,	  which	  is	  why	  averages	  including	  all	  samples	  are	  
given.	   Free	   DOX	   exhibited	   higher	   cytotoxicity	   at	   most	   of	   the	  
concentrations,	   only	   at	   the	   highest	   concentration	   (9	   µg/mL)	  
there	  was	  no	  significant	  difference	  found	  to	  DOX	  delivered	  via	  
reduction-­‐sensitive	   nanoparticles.	   The	   cytotoxicity	   of	   DOX-­‐
loaded	  PMOXA-­‐g(SS)-­‐PCL	  nanoparticles	  is	  clearly	  related	  to	  the	  
action	  of	  released	  DOX	  due	  to	  the	  non-­‐toxic	  nature	  of	  PMOXA-­‐
g(SS)-­‐PCLs	  up	  to	  1	  mg/mL	  (Fig.	  4D);	  maximum	  concentration	  of	  
polymer	   used	   within	   the	   DOX	   cytotoxicity	   assays	   was	   0.07	  
mg/mL.	   The	   reduction-­‐responsive	   nanoparticles	   efficiently	  
deliver	   DOX	   to	   cancer	   cells	   to	   reach	   the	   full	   potential	   of	   the	  
drug	   (Fig.	   4E)	   while	   protecting	   it	   in	   the	   surrounding	  medium	  
(Fig.	  3C,	  S15).	  This	  will	  allow	  reducing	  the	  toxic	  side	  effects	  of	  
DOX	  by	  keeping	  the	  drug	  within	  the	  stable	  nanoparticles	  after	  
intravenous	   application	   –	   restricting	   vast	   distribution	   of	   the	  
drug	  –	   followed	  by	  passive	  accumulation	  within	   tumor	   tissue,	  
uptake	   by	   cancer	   cells	   and	   subsequent	   efficient	   intracellular	  
release	  of	  the	  drug.	  	  
	  
Drug	  delivery	  to	  Plasmodium	  falciparum-­‐infected	  red	  blood	  
cells	  	  
Another	   disease	   model	   was	   used	   to	   study	   the	   broad	  
applicability	   of	   the	   reduction-­‐sensitive	   PMOXA-­‐g(SS)-­‐PCL	  
nanoparticle	   platform	   for	   smart	   drug	   delivery.	   Several	  
pathways	   for	   the	   efficient	   nanoparticle	   uptake	   by	   parasitized	  
RBCs,	   which	   can	   be	   utilized	   to	   passively	   target	   drug-­‐loaded	  
nanostructures	   to	   iRBCs	   compared	   to	   RBCs,36,41,42	   have	   been	  
proposed.43	   However,	   it	   is	   still	   not	   clear	   which	   or	   which	  
combination	  of	  these	  mechanisms	  allow	  targeted	  antimalarial	  
delivery	   to	   iRBCs.	   Nevertheless,	   we	   make	   use	   of	   this	   iRBC	  
“leakiness”	  to	  deliver	  loaded	  nanoparticles	  specifically	  to	  iRBCs	  
compared	  to	  RBCs.	  	  
First,	   a	   model	   hydrophobic	   molecule,	   NileRed,	   was	  
encapsulated	   in	   reduction-­‐sensitive	   PMOXA-­‐g(SS)-­‐PCL	   3	  
nanoparticles	   and	   PMOXA-­‐b-­‐PCL	   nanoparticles	   to	   study	  
delivery	   of	   a	   model	   compound	   via	   fluorescence	   microscopy.	  
This	  hydrophobic	  dye	  molecule	  additionally	  serves	  as	  a	  model	  
for	  drug	  molecules	  with	  very	  low	  aqueous	  solubility,	  a	  property	  
of	   many	   experimental	   drugs	   at	   early	   stages	   of	   drug	  
development.	  After	  a	  short	  2	  h	  incubation	  of	  either	  free	  dye	  or	  
encapsulated	   dye	   with	   a	   mixture	   of	   RBCs	   and	   iRBCs	   (about	  
4%),	   a	   clear	   intracellular	  parasite	   staining	  was	  observed	   in	  all	  
cases,	   demonstrating	   the	   possible	   passively	   targeted	   delivery	  
of	   a	  model	  molecule	   to	   iRBCs	   using	   small	   nanoparticles	   (Fig.	  
5B,	  S19).	  The	  dye	  is	  preferentially	  found	  in	  iRBCs	  compared	  to	  
normal	  RBCs,	  which	  demonstrates	  a	  passive	  targeting.	  Further	  
increase	   of	   iRBC	   targeting	   might	   be	   achieved	   by	   including	  
additional	   targeting	   ligands	   (e.g.	   antibodies)	   on	   the	  
nanostructure.61	  Since	  the	  passive	  targeting	  to	  iRBCs	  is	  already	  
pronounced	  for	  non-­‐targeted	  nanostructures,61	  as	  also	  shown	  
herein,	  it	  allows	  to	  design	  less	  expensive	  drug	  carriers.	  The	  fast	  
delivery	  of	  a	  model	  compound	  to	  iRBCs	  without	  any	  targeting	  
ligands	   on	   the	  nanoparticle	   surface	   indicates	   the	  potential	   of	  
inert,	   protein-­‐repellant	   PMOXA-­‐coated	   nanoparticles	   for	  
passively	   targeted	   antimalarial	   delivery	   to	   Plasmodium-­‐
infected	  RBCs.	  	  
Fluorescence	   intensities	   were	   in	   general	   higher	   within	  
schizonts	   compared	   to	   trophozoite	   stage	   parasites	   (Fig.	   S19).	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The	  staining	  pattern	  shows	  accumulation	  of	  the	  dye	  in	  certain	  
parasite	   compartments.	   This	   specific	   dye	   is	   known	   to	  
accumulate	  in	  neutral	  lipid	  bodies,	  which	  were	  proposed	  to	  be	  
storage	   organelles	   for	   lipid	   intermediates.62	   This	   staining	  
pattern	  is	  also	  common	  in	  other	  cell	  types	  such	  as	  yeast	  cells.63	  
The	  observation	  of	  this	  lipid	  body	  staining	  also	  in	  nanoparticle	  
samples	   suggests	   successful	   release	   of	   the	   dye	   from	  
nanoparticles.	   Combined	   with	   the	   high	   medium	   stability	   of	  
both	   particles	   for	   several	   days	   (Fig.	   3C,	   S15)	   it	   can	   be	  
speculated	   that	   nanoparticles	   are	   taken	   up	   and	   the	   dye	   is	  
subsequently	   released.	   This	   delivery	   mechanism	   was	   also	  
proposed	   by	   other	   research	   groups.36,41,42	   To	   reflect	   the	  
potency	   of	   nanoparticle-­‐based	   stabilization	   and	   delivery	   of	  
small	  compounds,	  a	  one-­‐day-­‐old	  NileRed	  aqueous	  solution	  was	  
additionally	   tested	   in	   the	   same	  way	  and	  compared	   to	  a	   fresh	  
NileRed	   solution.	   It	   clearly	   showed	   that	   this	   model	  
hydrophobic	  compound	  was	  not	  stable	  enough	  in	  solution	  for	  
one	   day;	   it	   did	   not	   readily	   appear	   in	   the	   iRBCs	   compared	   to	  
fresh	  dye	  (Fig.	  S20).	  
Similarly,	   an	   experimental	   antimalarial	   compound	   (SHMT	  
inhibitor	   (±)-­‐1,	   Scheme	   1),32	  which	   is	   very	   active	   in	   vitro,	   but	  
with	  an	  intrinsic	  solubility	  and	  metabolic	  stability	  problem	  that	  
hampers	   successful	   in	   vivo	   application,32	   was	   incorporated	  
within	   reduction-­‐sensitive	   and	   non-­‐sensitive	   nanoparticles.	  
With	   our	   nanoparticles,	   we	   could	   stabilize	   the	   drug	   up	   to	  
concentrations	   of	   about	   300	   µM,	  whereas	   the	   free	   drug	  was	  
not	   readily	   soluble	   in	   PBS,	   it	   visibly	   precipitated	   as	   shown	   in	  
digital	   images	   at	   a	   concentration	   of	   10	   µM	   drug	   in	   PBS	   (Fig.	  
S21).	   iRBCs	   and	   uninfected	   RBCs	   under	   shaking	   conditions	  
were	  used	  as	  an	  in	  vitro	  system	  that	  more	  closely	  simulates	  the	  
in	   vivo	   situation	   compared	   to	   standard	   static	  drug	   testing	   for	  
antimalarials,64	  which	  was	   additionally	   performed	   (Fig.	   5C,D).	  
Only	   PMOXA-­‐g(SS)-­‐PCL	   3	   and	   PMOXA-­‐b-­‐PCL	   nanoparticles	  
were	   used	   for	   antimalarial	   testing,	   because	   there	   were	   no	  
significant	  differences	  found	  for	  the	  three	  graft	  copolymers	  in	  
terms	  of	  drug	  delivery	  to	  cancer	  cells	  (Fig.	  4).	  Solubilization	  and	  
potential	  protection	  from	  metabolic	  degradation	  are	  the	  main	  
reasons	   for	   SHMT	   inhibitor	   (±)-­‐1	   encapsulation	   in	  
nanoparticles.	  	  
We	   demonstrated	   that	   over	   two	   parasite	   cycles	   (four	   day	  
suspension	   assay,	   5%	   hematocrit)	   the	   drug	   reached	   its	   full	  
potential	   when	   delivered	   via	   nanoparticles	   (Fig.	   5D).	   For	  
shorter	   incubation	   times	   (one	   day	   suspension	   assay,	   10%	  
hematocrit,	   Fig.	   5C,D),	   the	  drug	  was	  more	   active	   followed	  by	  
drug	   delivery	   via	   reduction-­‐sensitive	   nanoparticles	   and	   non-­‐
sensitive	   nanoparticles.	   The	   results	  were	   similar	  when	   tested	  
	  
Fig.	  5	  Dye	  and	  drug	  delivery	  to	  Plasmodium-­‐infected	  red	  blood	  cells	  (iRBCs).	  (A)	  Schematic	  representation	  of	  SHMT	  inhibitor	  (±)-­‐1	  delivery	  to	  iRBCs	  using	  reduction-­‐responsive	  
PMOXA-­‐g(SS)-­‐PCL	  nanoparticles.	  (B)	  Fluorescence	  imaging	  demonstrating	  delivery	  of	  hydrophobic	  model	  molecule,	  NileRed,	  using	  PMOXA-­‐g(SS)-­‐PCL	  3	  nanoparticles:	  DIC	  (top	  
left),	  Hoechst	  DNA-­‐stain	  (top	  right),	  NileRed	  signal	  (bottom	  left),	  merge	  (bottom	  right).	  (C)	  Example	  of	  dose-­‐response	  curves	  for	  one-­‐day	  suspension	  antimalarial	  assay	  with	  
free	  SHMT	  inhibitor	  (±)-­‐1	  or	  nanoparticle-­‐based	  delivery.	  (D)	  Comparison	  of	  IC50	  values	  for	  all	  the	  different	  antimalarial	  assay	  conditions	  and	  samples	  presented	  as	  the	  average	  
±	  SEM	  (n	  ≥	  3).	  Statistics	  were	  analyzed	  using	  two-­‐tailed	  Student’s	  t-­‐test:	  *P<0.05,	  **P<0.01,	  ***P<0.001.	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in	   standard	   antimalarial	   drug	   testing	   assays	   (three	   day	   static	  
assay,	  1.25%	  hematocrit).	   In	   these	   in	  vitro	   settings,	  where	  no	  
other	   cells	   apart	   from	   RBCs	   and	   iRBCs	   were	   present,	  
developed	   antimalarials	   intrinsically	   target	   the	   iRBCs	   and	  
uptake	   of	   bigger	   nanoparticles	   is	   slower	   compared	   to	   small	  
molecule	   uptake.	   However,	   nanoparticles	   (<	   80	   nm	  
diameter)36,41,42	  also	  passively	  target	  iRBCs	  compared	  to	  RBCs.	  
This	   explains	   the	   delivery	   profile	   obtained	   with	   our	   drug	  
delivery	  system,	  which	  indicates	  a	  somewhat	  delayed	  delivery	  
of	   the	   antimalarial	   when	   delivered	   to	   iRBCs	   using	  
nanoparticles.	  The	  mechanism	  of	  uptake	  has	   to	  be	   studied	   in	  
more	   detail	   in	   the	   future.	   Nevertheless,	   the	   delivery	   profile	  
obtained	  with	  our	  nanoparticle	  platform	  can	  be	  advantageous	  
as	   demonstrated	   for	   artemisinin-­‐loaded	   liposomes.65,66	   The	  
liposomal	   formulation	   of	   artemisinin	   allowed	   to	   achieve	   a	  
more	   stable	   drug	   concentration	   in	   the	   bloodstream	   and	  
immediate	  effect	  on	  the	  parasites	  compared	  to	  free	  drug	  that	  
was	  rapidly	  eliminated	  from	  the	  blood	  and	  only	  had	  an	  effect	  
on	   the	   parasites	   several	   days	   after	   treatment	   start.65,66	  
Compared	  to	  artemisinin,	  the	  SHMT	  inhibitor	  (±)-­‐1	  used	  herein	  
is	  not	  active	  at	  all	  against	  malaria	   in	  vivo.32	  Therefore,	  slightly	  
higher	   in	   vitro	   activity	   of	   the	   free	   drug	   compared	   to	  
nanoparticle-­‐stabilized	   drug	   has	   to	   be	   seen	   from	   another	  
angle.	  The	  nanoparticles	  solubilize	  and	  can	  further	  protect	  the	  
drug	   from	   fast	   degradation,	   which	   will	   overcompensate	   the	  
slightly	   slower	   uptake	   and	   activity	   of	   nanoparticle-­‐based	  
delivery.	   The	   chemical	   nature	   of	   the	   PMOXA-­‐based	  
nanoparticles	   provides	   the	   basis	   for	   prolonged	   circulation	  
times	  in	  the	  blood,15,17,18	  and	  the	  hydrophobic	  core	  shields	  the	  
drug	   from	   the	  environment	  before	  entering	   iRBCs;	   this	   is	   not	  
possible	  with	  free	  SHMT	  inhibitor	  (±)-­‐1.32	  An	  additional	  benefit	  
of	   reduction-­‐triggered	   delivery	   of	   antimalarials	   via	  
nanoparticles	   would	   be	   the	   faster	   and	   more	   efficient	   drug	  
release	   within	   even	  more	   reducing	   cytosols	   of	   drug-­‐resistant	  
parasites	  compared	  to	  drug-­‐sensitive	  strains.45,46	  
Our	   nanoparticle	   platform	   holds	   the	   promise	   to	   efficiently	  
solubilize	   and	   delay	   fast	   liver	   degradation	   of	   experimental	  
antimalarial	  drug	   candidates,	   in	  order	   to	   reach	  a	  more	   stable	  
drug	   blood	   drug	   concentration	   compared	   to	   free	   drug	  
administration.	   These	   observations	   provide	   the	   basis	   for	  
further	   optimization	   and	   application	   of	   nanoparticles	   for	  
stabilizing,	   protecting,	   and	   delivering	   water-­‐insoluble,	   labile	  
drugs	   already	   at	   early	   stages	   of	   drug	   development.	   This	  
represents	   a	   highly	   promising	   alternative	   to	   optimization	   of	  
the	  drug	  itself	  and	  can	  be	  applied	  to	  other	  anticancer	  and	  anti-­‐
infectious	  drugs.	  
Conclusions	  
A	   library	   of	   reduction	   responsive	   PMOXA-­‐g(SS)-­‐PCL	  
amphiphilic	   block	   copolymers	   was	   synthesized	   through	   the	  
thiol-­‐disulfide	   exchange	   reaction	   between	   thiolated	   PMOXA	  
(PMOXA-­‐SH)	   and	   pyridyl	   disulfide	   functionalized	   poly(ε-­‐
caprolactone)	   (PCL-­‐co-­‐PPCL).	   This	   type	   of	   copolymers	   self-­‐
assembled	   into	  nanoparticles	  with	  sizes	  around	  50	  nm.	  These	  
nanoparticles	   did	   not	   reveal	   any	   cytotoxicity	   in	   the	   tested	  
concentration	   range,	   providing	   a	   biocompatible,	  
biodegradable,	   and	   reduction-­‐triggerable	   platform	   for	   smart	  
drug	   delivery.	   Detailed	   stability	   and	   release	   studies	   using	  
nanoparticle-­‐incorporated	   model	   compounds	   demonstrated	  
high	  colloidal	  stability	  and	  guest	  molecule	  retention	  within	  the	  
nanostructures	   when	   incubated	   in	   various	   cell	   media	   at	  
physiological	   temperature	   for	   four	   days.	   Rapid	   release	   of	   the	  
guest	   molecules	   was	   achieved	   upon	   treatment	   with	  
biologically	   relevant	   reducing	   agent	   concentrations.	   This	  
designed	   nanoparticle	   platform	   was	   successfully	   used	   to	  
deliver	   hydrophobic,	   toxic	   anticancer	   drugs	   to	   cancer	   cells.	  
Additionally,	   this	   nanoparticle	   platform	   was	   evaluated	   to	  
solubilize	   and	   deliver	   a	   hydrophobic,	   metabolically	   unstable,	  
experimental	   antimalarial	   drug	   to	  Plasmodium-­‐infected	   RBCs,	  
which	  was	  successfully	  achieved.	  Our	  new	  reduction-­‐sensitive	  
amphiphilic	  copolymers	  are	  promising	  candidate	  materials	   for	  
targeted	  drug	  delivery	   purposes	   to	   tackle	   cancer	   and	  malaria	  
with	  a	  sophisticated	  smart	  delivery	  platform.	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